{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:39:08Z","timestamp":1791308348951,"version":"4.3.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["NSFC No. 82000516"],"award-info":[{"award-number":["NSFC No. 82000516"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["NSFC No. 82201198"],"award-info":[{"award-number":["NSFC No. 82201198"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Zhejiang Provincial Traditional Chinese Medicine Science and Technology Project","award":["2022ZB271"],"award-info":[{"award-number":["2022ZB271"]}]},{"name":"the Westlake University School of Medicine Junior Physician-Scientist Cultivation Program","award":["WU2024B009"],"award-info":[{"award-number":["WU2024B009"]}]},{"DOI":"10.13039\/501100002858","name":"The China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2023M743009"],"award-info":[{"award-number":["2023M743009"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Zhejiang Provincial Natural Science Foundation of China","award":["LTGY23H120004"],"award-info":[{"award-number":["LTGY23H120004"]}]},{"name":"The Zhejiang Province Medical and Health Technology Project","award":["2023RC056"],"award-info":[{"award-number":["2023RC056"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Beh\u00e7et\u2019s disease (BD) is a chronic, recurrent condition for which effective preventive medications are currently lacking. This disease often disrupts lipid metabolism, adversely affecting vascular endothelial function. Exploring preventive strategies, such as lipid-lowering medications, is crucial. Probucol, known for its lipid-lowering properties, emerges as a promising candidate. By inhibiting the ATP-binding cassette transporter A1 (ABCA1), probucol is hypothesized to regulate circulating metabolites, potentially reducing the risk of BD. This study employs Mendelian randomization (MR) to evaluate probucol\u2019s impact on BD and investigate its preventive potential through the modulation of circulating metabolites. For this MR study, we selected single nucleotide polymorphisms (SNPs) associated with probucol as instrumental variables and conducted a positive control analysis with SNPs linked to high-density lipoprotein (HDL) to validate our instrument selection. The study was structured in two steps: first, using probucol\u2019s eQTLs to estimate its causal effect on circulating metabolites; second, using SNPs linked to these metabolites to assess their causal impact on Behcet\u2019s disease risk. To ensure the robustness and validity of our findings, we employed several MR methods, including the Inverse Variance Weighted (IVW) approach, heterogeneity tests, and pleiotropy analysis. This study identified a total of 30 SNPs associated with BD, 7502 SNPs linked to circulating metabolites, and 1,049 SNPs associated with BD from circulating metabolites, all derived from ABCA1 expression quantitative trait loci (eQTL) data. Utilizing Mendelian randomization (MR) analysis, it was confirmed that probucol leads to a reduction in concentrations of cholesterol esters in HDL, consistent with findings from randomized drug trials (odds ratio [OR]\u2009=\u20090.932, 95% confidence interval [CI] 0.907\u20130.958, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Furthermore, the study demonstrated that probucol significantly decreased the risk of BD with an OR of 0.496 (95% CI 0.283\u20130.868, <jats:italic>P<\/jats:italic>\u2009=\u20090.014). Among 123 assessed circulating metabolites, thirty-six were found to be associated with probucol. Notably, probucol demonstrated a notable reduction in very large HDL particle concentrations (OR\u2009=\u20090.917, 95% CI 0.889\u20130.947, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), contributing to approximately 10.407% of its overall impact on decreasing BD risk. This study establishes that probucol significantly lowers the risk of BD by reducing very large HDL particle concentrations. It provides a genetic basis for considering probucol as a potential therapeutic option for BD high risk individuals.<\/jats:p>","DOI":"10.1038\/s41598-025-93644-8","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T05:13:16Z","timestamp":1742533996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mendelian randomization reveals probucol\u2019s preventive role in Beh\u00e7et\u2019s disease via circulating metabolites"],"prefix":"10.1038","volume":"15","author":[{"given":"Zhang","family":"Hongchen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Yijia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Jianguang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun","family":"Mouyuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"issue":"2","key":"93644_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/intimm\/dxt046","volume":"26","author":"\u015e Y\u00fcksel","year":"2014","unstructured":"Y\u00fcksel, \u015e et al. Novel NLRP3\/cryopyrin mutations and pro-inflammatory cytokine profiles in Beh\u00e7et\u2019s syndrome patients. Int. Immunol. 26(2), 71\u201381. https:\/\/doi.org\/10.1093\/intimm\/dxt046 (2014).","journal-title":"Int. Immunol."},{"issue":"4","key":"93644_CR2","first-page":"227","volume":"17","author":"K Hamzaoui","year":"2011","unstructured":"Hamzaoui, K. et al. Expression of Th-17 and ROR\u03b3t mRNA in Beh\u00e7et\u2019s disease. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 17(4), 227\u2013234 (2011).","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"issue":"2","key":"93644_CR3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/rheumatology\/kes249","volume":"52","author":"AJ Mohammad","year":"2013","unstructured":"Mohammad, A. J., Mandl, T., Sturfelt, G. K. & Segelmark, M. Incidence, prevalence and clinical characteristics of Behcet\u2019s disease in southern Sweden. Rheumatology 52(2), 304\u2013310 (2013).","journal-title":"Rheumatology"},{"issue":"1","key":"93644_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/art.22500","volume":"57","author":"C Salvarani","year":"2007","unstructured":"Salvarani, C. et al. Epidemiology and clinical course of Beh\u00e7et\u2019s disease in the Reggio Emilia area of Northern Italy: A seventeen-year population-based study. Arthritis Rheumat. 57(1), 171\u2013178. https:\/\/doi.org\/10.1002\/art.22500 (2007).","journal-title":"Arthritis Rheumat."},{"key":"93644_CR5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s12016-021-08864-3","volume":"61","author":"J-J Chen","year":"2021","unstructured":"Chen, J.-J. & Yao, X. A contemporary review of Behcet\u2019s syndrome. Clin. Rev. Allerg. Immunol. 61, 363\u2013376 (2021).","journal-title":"Clin. Rev. Allerg. Immunol."},{"key":"93644_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/oarrr.s46644","volume":"7","author":"R Rokutanda","year":"2015","unstructured":"Rokutanda, R., Kishimoto, M. & Okada, M. Update on the diagnosis and management of Beh\u00e7et\u2019s disease. Open Access Rheumatol. Res. Rev. 7, 1\u20138. https:\/\/doi.org\/10.2147\/oarrr.s46644 (2015).","journal-title":"Open Access Rheumatol. Res. Rev."},{"issue":"1","key":"93644_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41572-021-00301-1","volume":"7","author":"Y Yazici","year":"2021","unstructured":"Yazici, Y. et al. Beh\u00e7et syndrome. Nat. Rev. Dis. Prim. 7(1), 67. https:\/\/doi.org\/10.1038\/s41572-021-00301-1 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"1","key":"93644_CR8","doi-asserted-by":"publisher","first-page":"12735","DOI":"10.1038\/s41598-022-17096-0","volume":"12","author":"YH Kim","year":"2022","unstructured":"Kim, Y. H. et al. Risk for Beh\u00e7et\u2019s disease gauged via high-density lipoprotein cholesterol: A nationwide population-based study in Korea. Sci. Rep. 12(1), 12735. https:\/\/doi.org\/10.1038\/s41598-022-17096-0 (2022).","journal-title":"Sci. Rep."},{"issue":"4","key":"93644_CR9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5152\/eurjrheum.2023.23062","volume":"10","author":"\u00c7 Y\u00fccel","year":"2023","unstructured":"Y\u00fccel, \u00c7. et al. Comparative metabolomic profiles of vascular involvement in Beh\u00e7et\u2019s disease. Eur. J. Rheumatol. 10(4), 130\u2013135. https:\/\/doi.org\/10.5152\/eurjrheum.2023.23062 (2023).","journal-title":"Eur. J. Rheumatol."},{"key":"93644_CR10","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1161\/01.ATV.0000148706.15947.8a","volume":"24","author":"E Favari","year":"2004","unstructured":"Favari, E. et al. Probucol inhibits ABCA1-mediated cellular lipid efflux. Arterioscler. Thromb. Vasc. Biol. 24, 2345\u20132350 (2004).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"93644_CR11","doi-asserted-by":"publisher","first-page":"30168","DOI":"10.1074\/jbc.M403765200","volume":"279","author":"C-a Wu","year":"2004","unstructured":"Wu, C.-a, Tsujita, M., Hayashi, M. & Yokoyama, S. Probucol inactivates ABCA1 in the plasma membrane with respect to its mediation of apolipoprotein binding and high density lipoprotein assembly and to its proteolytic degradation. J. Biol. Chem. 279, 30168\u201330174 (2004).","journal-title":"J. Biol. Chem."},{"key":"93644_CR12","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1194\/jlr.M900122-JLR200","volume":"50","author":"R Arakawa","year":"2009","unstructured":"Arakawa, R. et al. Pharmacological inhibition of ABCA1 degradation increases HDL biogenesis and exhibits antiatherogenesis. J. Lipid Res. 50, 2299\u20132305 (2009).","journal-title":"J. Lipid Res."},{"key":"93644_CR13","doi-asserted-by":"publisher","first-page":"471590","DOI":"10.1155\/2011\/471590","volume":"2011","author":"AA Al-Majed","year":"2011","unstructured":"Al-Majed, A. A. Probucol attenuates oxidative stress, energy starvation, and nitric acid production following transient forebrain ischemia in the rat hippocampus. Oxid. Med. Cell. Longev. 2011, 471590. https:\/\/doi.org\/10.1155\/2011\/471590 (2011).","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"1","key":"93644_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40035-024-00398-w","volume":"13","author":"A Sharif","year":"2024","unstructured":"Sharif, A. et al. The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases. Transl. Neurodegen. 13(1), 6. https:\/\/doi.org\/10.1186\/s40035-024-00398-w (2024).","journal-title":"Transl. Neurodegen."},{"key":"93644_CR15","doi-asserted-by":"publisher","first-page":"5558066","DOI":"10.1155\/2021\/5558066","volume":"2021","author":"G Han","year":"2021","unstructured":"Han, G., Zhang, Y. & Li, H. The combination treatment of curcumin and probucol protects chondrocytes from TNF-\u03b1 induced inflammation by enhancing autophagy and reducing apoptosis via the PI3K-Akt-mTOR pathway. Oxid. Med. Cell. Longev. 2021, 5558066. https:\/\/doi.org\/10.1155\/2021\/5558066 (2021).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"93644_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejphar.2017.05.016","volume":"809","author":"AZ Zucoloto","year":"2017","unstructured":"Zucoloto, A. Z. et al. Probucol attenuates lipopolysaccharide-induced leukocyte recruitment and inflammatory hyperalgesia: Effect on NF-\u043aB activation and cytokine production. Eur. J. Pharmacol. 809, 52\u201363. https:\/\/doi.org\/10.1016\/j.ejphar.2017.05.016 (2017).","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"93644_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2004.01.027","volume":"174","author":"S Nomura","year":"2004","unstructured":"Nomura, S. et al. Probucol and ticlopidine: Effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes. Atherosclerosis 174(2), 329\u2013335 (2004).","journal-title":"Atherosclerosis"},{"issue":"5","key":"93644_CR18","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0022-2275(20)33877-3","volume":"39","author":"DA Bird","year":"1998","unstructured":"Bird, D. A. et al. Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice. J. Lipid Res. 39(5), 1079\u20131090 (1998).","journal-title":"J. Lipid Res."},{"key":"93644_CR19","first-page":"4322","volume":"16","author":"Y Chen","year":"2018","unstructured":"Chen, Y. et al. Probucol protects circulating endothelial progenitor cells from ambient PM2.5 damage via inhibition of reactive oxygen species and inflammatory cytokine production in vivo. Exp. Therap. Med. 16, 4322\u20134328 (2018).","journal-title":"Exp. Therap. Med."},{"issue":"19","key":"93644_CR20","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1001\/jama.2017.17219","volume":"318","author":"CA Emdin","year":"2017","unstructured":"Emdin, C. A., Khera, A. V. & Kathiresan, S. Mendelian randomization. JAMA 318(19), 1925\u20131926. https:\/\/doi.org\/10.1001\/jama.2017.17219 (2017).","journal-title":"JAMA"},{"issue":"2","key":"93644_CR21","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/ije\/dyv108","volume":"44","author":"S Burgess","year":"2015","unstructured":"Burgess, S., Timpson, N. J., Ebrahim, S. & Davey, S. G. Mendelian randomization: Where are we now and where are we going?. Int. J. Epidemiol. 44(2), 379\u2013388. https:\/\/doi.org\/10.1093\/ije\/dyv108 (2015).","journal-title":"Int. J. Epidemiol."},{"issue":"16","key":"93644_CR22","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1001\/jama.2021.18236","volume":"326","author":"VW Skrivankova","year":"2021","unstructured":"Skrivankova, V. W. et al. Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: The STROBE-MR statement. Jama 326(16), 1614\u20131621. https:\/\/doi.org\/10.1001\/jama.2021.18236 (2021).","journal-title":"Jama"},{"issue":"11","key":"93644_CR23","doi-asserted-by":"publisher","first-page":"e1009922","DOI":"10.1371\/journal.pgen.1009922","volume":"17","author":"Z Lin","year":"2021","unstructured":"Lin, Z., Deng, Y. & Pan, W. Combining the strengths of inverse-variance weighting and Egger regression in Mendelian randomization using a mixture of regressions model. PLoS Genet. 17(11), e1009922. https:\/\/doi.org\/10.1371\/journal.pgen.1009922 (2021).","journal-title":"PLoS Genet."},{"key":"93644_CR24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.12688\/wellcomeopenres.15555.3","volume":"4","author":"S Burgess","year":"2019","unstructured":"Burgess, S. et al. Guidelines for performing Mendelian randomization investigations: Update for summer. Wellcome Open Res. 4, 186. https:\/\/doi.org\/10.12688\/wellcomeopenres.15555.3 (2019).","journal-title":"Wellcome Open Res."},{"issue":"1","key":"93644_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1037\/1082-989x.7.1.83","volume":"7","author":"DP MacKinnon","year":"2002","unstructured":"MacKinnon, D. P., Lockwood, C. M., Hoffman, J. M., West, S. G. & Sheets, V. A comparison of methods to test mediation and other intervening variable effects. Psychol. Methods 7(1), 83\u2013104. https:\/\/doi.org\/10.1037\/1082-989x.7.1.83 (2002).","journal-title":"Psychol. Methods"},{"issue":"5","key":"93644_CR26","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","volume":"50","author":"M Verbanck","year":"2018","unstructured":"Verbanck, M., Chen, C. Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat. Genet. 50(5), 693\u2013698. https:\/\/doi.org\/10.1038\/s41588-018-0099-7 (2018).","journal-title":"Nat. Genet."},{"issue":"4","key":"93644_CR27","doi-asserted-by":"publisher","first-page":"e0124021","DOI":"10.1371\/journal.pone.0124021","volume":"10","author":"J Liu","year":"2015","unstructured":"Liu, J. et al. Effects of probucol on restenosis after percutaneous coronary intervention: A systematic review and meta-analysis. PloS One 10(4), e0124021. https:\/\/doi.org\/10.1371\/journal.pone.0124021 (2015).","journal-title":"PloS One"},{"issue":"3","key":"93644_CR28","doi-asserted-by":"publisher","first-page":"27B","DOI":"10.1016\/S0002-9149(88)80047-X","volume":"62","author":"AL Drash","year":"1988","unstructured":"Drash, A. L., Rudert, W. A., Borquaye, S., Wang, R. & Lieberman, I. Effect of probucol on development of diabetes mellitus in BB rats. Am. J. Cardiol. 62(3), 27B-30B (1988).","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"93644_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/rheumatology\/38.4.309","volume":"38","author":"CP Denton","year":"1999","unstructured":"Denton, C. P. et al. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud\u2019s phenomenon. Rheumatology (Oxford, England) 38(4), 309\u2013315. https:\/\/doi.org\/10.1093\/rheumatology\/38.4.309 (1999).","journal-title":"Rheumatology (Oxford, England)"},{"key":"93644_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/cpt1974161part144","volume":"16","author":"HB Brown","year":"1974","unstructured":"Brown, H. B. & deWolfe, V. G. The additive effect of probucol on diet in hyperlipidemia. Clin. Pharmacol. Therap. 16, 44 (1974).","journal-title":"Clin. Pharmacol. Therap."},{"issue":"7","key":"93644_CR31","doi-asserted-by":"publisher","first-page":"643","DOI":"10.5551\/jat.12807","volume":"19","author":"M Inagaki","year":"2012","unstructured":"Inagaki, M. et al. Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia. J. Atheroscler. Thromb. 19(7), 643\u2013656 (2012).","journal-title":"J. Atheroscler. Thromb."},{"issue":"8","key":"93644_CR32","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1161\/01.ATV.15.8.1057","volume":"15","author":"LS Elinder","year":"1995","unstructured":"Elinder, L. S. et al. Probucol treatment decreases serum concentrations of diet-derived antioxidants. Arterioscler. Thromb. Vasc. Biol. 15(8), 1057\u20131063 (1995).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"93644_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00218","author":"A Kontush","year":"2015","unstructured":"Kontush, A. HDL particle number and size as predictors of cardiovascular disease. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2015.00218 (2015).","journal-title":"Front. Pharmacol."},{"key":"93644_CR34","doi-asserted-by":"publisher","first-page":"10645","DOI":"10.3390\/ijms241310645","volume":"24","author":"C-K Chang","year":"2023","unstructured":"Chang, C.-K. et al. The sizes and composition of HDL-cholesterol are significantly associated with inflammation in rheumatoid arthritis patients. Int. J. Mol. Sci. 24, 10645 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"93644_CR35","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1161\/ATVBAHA.113.301468","volume":"33","author":"L Camont","year":"2013","unstructured":"Camont, L. et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: Relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler. Thrombosis Vasc. Biol. 33, 2715\u20132723 (2013).","journal-title":"Arterioscler. Thrombosis Vasc. Biol."},{"key":"93644_CR36","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/ar2471","volume":"10","author":"BH Hahn","year":"2008","unstructured":"Hahn, B. H., Grossman, J. M., Ansell, B. J., Skaggs, B. J. & McMahon, M. Altered lipoprotein metabolism in chronic inflammatory states: Proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res. Ther. 10, 213 (2008).","journal-title":"Arthritis Res. Ther."},{"issue":"4","key":"93644_CR37","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.reumae.2023.12.006","volume":"20","author":"C Moriano Morales","year":"2024","unstructured":"Moriano Morales, C. et al. SER recommendations on treatment of refractory Beh\u00e7et\u2019s syndrome. Reumatol. Clin. 20(4), 204\u2013217. https:\/\/doi.org\/10.1016\/j.reumae.2023.12.006 (2024).","journal-title":"Reumatol. Clin."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93644-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93644-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93644-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T05:13:26Z","timestamp":1742534006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93644-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["93644"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-93644-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"10 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The summary-level GWAS statistics utilized in this study are publicly available, and no specific ethical approval was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"9722"}}